Home / current
Trials
Treatment Guidelines
PENTA Network
Publications
Key publications
2008
2007
2006
2005
2004
2003
2002
2001
2000
1998
All
publications
Other activities
Contacts
Risk calculator
Links
Area for PENTA network members (password
needed)
Updated 9 May, 2008
2008
Cressey TR, Green H, Khoo S, Treluyer J-M, Compagnucci A, Saidi Y, Lallement M, Gibb DM, Burger D. Plasma drug concentrations and virologic evaluations after stopping non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1 infected children. Clin Infect Dis. 2008 May 15;46(10):1601-8 (Reference)
Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee. Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS. 2008 Jan 2;22(1):97-105. (Reference)
Dunn DT, Woodburn P, Duong T, Phillips AN, Gibb D, Porter K on behalf of HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) and the CASCADE Collaboration. A comparison of the rate of clinical disease progression in HIV-infected children and adults allowing for current CD4 cell count. Journal Infectious Diseases 2008 Feb 1;197(3):398-404 (Reference)
2007
Gibb DM, Green H, Saidi Y, Pillay D, Compagnucci A, Harper L, Walker AS, Castelli-Gattinara G, Della Negra M, Levy J, Candeias F, Butler K, Feiterna-Sperling C, Wintergerst U, Giaquinto C on behalf of PENTA 5. 3TC+ABC maintains virological superiority over ZDV+3TC and ZDV+ABC beyond 5 years in children: the PENTA 5 trial. AIDS 2007; 21:947-955 (Reference)
2006
Aboulker J-P, Babiker A, Bacheler L, Burger D, Castelli-Gattinara G, Compagnucci A, Debré M, Della Negra M, Dunn DT, Giacomet V, Giaquinto C, Gibb DM, Green H, Harper L, Lyall H, Pillay D, de Rossi A, Rosso R, Saïdi Y, Walker AS on behalf of the PENTA 8 study group. A randomised controlled trial of genotypic HIV drug resistance testing in HIV-1 infected children: the PERA (PENTA 8) Trial. Antiviral Therapy 2006; 11:857-867 (.pdf file)
LeProvost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM on behalf of the PENTA 13 study group. Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children. PIDJ 2006;25:533-537 (Reference)
HIV Paediatric Prognostic Markers Collaborative Study.
Predictive value of absolute CD4 cell count for disease progression in
untreated HIV-1-infected children. AIDS 2006; 20:1289-1294 (Reference)
2005
Giaquinto C, Green H, De Rossi A, Saïdi Y, Compagnucci A, Girard S, Castelli-Gattinara G, della Negra M, Pinto J, De Souza Marques HH, Lyall EGH and Gibb DM on behalf of the PENTA 8 study group. A randomised trial of resistance testing versus no resistance testing in children with virological failure: the PERA (PENTA 8) trial. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Oral and poster presentation WeOa0106 (.pdf file)
Compagnucci A, Saïdi Y, Gibb DM, Rampon O, Ramos Amador JT, Feiterna Sperling C, Reliquet V, Giaquinto C, Navarro ML, Girard S, Harper L, Burger D, Treluyer JM, Aboulker JP, Jacqz-Aigrain E and Faye A on behalf of the PENTA 7 study group. Lower scores of Nelfinavir metabolite M8 were associated with virological failure vertically infected children in the PENTA 7study. 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Abstract MoPe9.2C15 (.pdf file)
Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Khoo S, Gibb DM on behalf of the PENTA 13 study group. Pharmacokinetics of once versus twice daily lamivudine and abacavir. Simplification of combination treatment in HIV-1 infected children (Penta 13). Antivir Ther. 2005;10:239-246. (.pdf file)
De Rossi A, Walker AS, De Forni D, Klein N, Dibb DM for PENTA. Relationship between changes in thymic emigrants and cell-associated HIV-1 DNA in HIV-1 infected children initiating antiretroviral therapy. Antivir Ther. 2005;10(1):63-71. (.pdf file)
HIV Paediatric Prognostic Markers Collaborative Study Group. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005; 366: 1868-74 (Reference)
2004
Burger DM, Bergshoeff A, de Groot R, Gibb DM, Walker AS, Tréluyer JM, Hoetelmans R, on behalf of the PENTA 5 study group. Maintaining the nelfinavir trough concentration above 0.8 mg/L significantly improves virological response in HIV-1-infected children. J Paediatr 2004; 145(3): 403-405. (.pdf file)
Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM for the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy 2004. HIV Med 2004; 5, (Suppl. 2), 61-86. (.pdf file)
Gibb DM, Melvin A, Compagnucci A, McKinney R, Tudor-Williams G, Walker AS, Harper L, Hodge J, Powell C, Green H, Saidi Y, Ortiz AA, Toye M, Girard S, Mofenson L, Giaquinto C, Hughes M on behalf of the PENPACT 1 Trial. Choice of first-line ART regimen in PENPACT 1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children >30 days and <18 years of age. XV International AIDS Conference, 11-16 July 2004, Bangkok. Poster TuPeB4442. (.pdf file)
Writing Committee (alphabetical): Aboulker J-P, Babiker A, Chaix ML, Compagnucci A, Darbyshire JH, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. 72-week follow-up of HAART started in infants aged less than 3 months: CD4, viral load and drug resistance outcomes in the PENTA 7 study. AIDS 2004; 18(2) 237-245 (Reference)
2003
HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1 infected children receiving no antiretroviral therapy or zidovudine monotherapy: estimates according to CD4 percent, viral load, and age. Lancet 2003, 362:1605-11(Reference)
Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E for PENTA. Pharmacokinetics of Nelfinavir and its Active Metabolite, hydroxy-tert-butylamide, in Infants Perinatally Infected with HIV-1. Pediatr Inf Dis J 2003; 22(1):48-55 (Reference)
Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H for PENTA. Adherence to Prescribed Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Children in the PENTA 5 Trial. Pediatr Inf Dis J 2003; 22 (1): 56-62 (Reference)
2002
Pillay D, Walker AS, Gibb DM, De Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A. for the PENTA Steering Committee. Impact of HIV-1 subtypes on virologic response and emergence of drug resistance. J Infect Dis 2002; 186:617-25 (.pdf file)*
Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez M, Loveday C, Compagnucci A, Dunn DT, Babiker A. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral naïve HIV-1 infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Antiviral Therapy 2002; 7(4): 293-303 (.pdf file)
De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM. Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial. J Infect Dis 2002; 186:312-20.(.pdf file)
De Rossi A, Walker AS, De Forni D, Gibb DM for PENTA. Biphasic decay of cell-associated HIV-1 DNA in HIV-1 infected children on antiretroviral therapy. AIDS 2002; 16:1961-63. (Reference)
Writing Committee (alphabetical): Aboulker J-P, Babiker A, Compagnucci A, Darbyshire JH, Debré M, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. A Randomised Trial to Compare Dual Nucleoside-Analogue Reverse Transcriptase Inhibitor Regimens (ZDV+3TC or ZDV+ABC or 3TC+ABC) With and Without a Protease Inhibitor (Nelfinavir) in Previously Untreated HIV-infected Children: The PENTA 5 Trial The Lancet 2002; 359, 733-740. (.pdf file)
2001
Writing Committee (alphabetical) Aboulker.J.P, Babiker. A., Darbyshire. J.H., Debre. M., Giaquinto.C., Gibb.D.M., Harper L., Newberry. A., Saidi.Y. Five-year follow-up of vertically HIV-infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001; 84: 230-236. (.pdf file)
King DJ, Gotch FM, Larsson-Sciard EL; Paediatric European Network for Treatment of AIDS (PENTA). T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART). Clin Exp Immunol. 2001 Sep;125(3):447-54. (Reference)
2000
Gibb DM, Newberry A, Klein N, de Rossi A, Grosch-Wörner I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1 infected children. The Lancet 2000; 355: 1331. (Reference)
1998
Writing Committee (alphabetical): Aboulker JP, Babiker A, Carrière I, Darbyshire JH Debré M, Giaquinto C, Gibb DM, Harper L, Newberry A, Saidi Y, Tudor-Williams G. A randomised double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. AIDS 1998; 12 F151-F160. (Reference)
Writing Committee: Gibb DM, Newberry A, De Rossi A, Kaye S, Loveday C, Muñoz-Fernandez, Rouzioux C, Debré M, Giaquinto C, Babiker A. HIV-1 Viral Load and CD4 Count in Untreated Children with Vertically Acquired Mild or Asymptomatic Disease - PENTA I Virology. AIDS 1998; 12 F1-F8. (Reference)
* acknowledges permission of the University of Chicago Press to reproduce the publication here